Norris Medicines Ltd Stock Price Today (NSE: NORRIS)

Norris Medicines Ltd

14.91+0.20 (+1.36%)
Market Closed

Fundamental Score

...

Norris Medicines Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Norris Medicines Ltd share price today is 14.91, up +1.36% on NSE/BSE as of 7 August 2026. Norris Medicines Ltd (NORRIS) is a Small-cap company in the Trading & Distributors sector with a market capitalisation of 15.70 (Cr). The 52-week high for NORRIS share price is 19.63 and the 52-week low is 12.00.

Norris Medicines Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
19.63
Low
14.25
Volume
2.2K
Change
-3.32%

Norris Medicines Ltd share price chart: -3.32% return over the past month. 52-week high ₹19.63, 52-week low ₹12.00.

Norris Medicines Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
14.8015.2514.8014.9191.00 (Cr)
14.0114.7114.0114.71587.00 (Cr)
13.7514.4313.7514.011.23K (Cr)
14.1414.1413.7513.75137.00 (Cr)
14.0014.9714.0014.1431.00 (Cr)
14.8914.8914.2514.26395.00 (Cr)
15.1315.1314.8214.82781.00 (Cr)
15.5016.2714.7515.13336.00 (Cr)
15.5016.0015.2015.50411.00 (Cr)
16.0016.0015.2016.00166.00 (Cr)

Norris Medicines Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
14.0015.2513.7514.91+6.50%
14.9119.6314.2514.26-4.36%
13.3114.9113.0014.84+11.50%
14.7514.9712.7513.25-10.17%
13.6215.6712.7614.25+4.63%
15.2715.2712.0013.35-12.57%
14.0015.5012.5015.23+8.79%
14.6017.0012.5014.20-2.74%
15.7519.2514.0015.95+1.27%
16.1217.0015.0015.00-6.95%
16.5017.5015.0015.80-4.24%
15.7617.9515.7516.06+1.90%

Returns & Performance

Return on Equity (ROE)

N/A

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

3.36%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

2.89%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Norris Medicines Ltd Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

21.65x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

34.01%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.07%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

121.74%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-48.16%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-7.87%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

14.21%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

14.21%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Debt to Equity Ratio

N/A

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

0.44x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

1.42 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Norris Medicines Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of NORRIS across key market metrics for learning purposes.

Positive Indicators

2 factors identified

Robust Profit Growth (121.74%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

7 factors identified

Suboptimal ROCE (3.36%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (2.89%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Revenue Contraction (-48.16%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Limited Growth History (-7.87% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Weak Interest Coverage (0.44x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Limited Institutional Interest (FII+DII: 0.07%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Norris Medicines Ltd vs Trading & Distributors Peers

Peer Comparison - Trading & Distributors

Compare Norris Medicines Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
18.4/100
15
₹15.70
3.36%
Poor
14.21%
Good
-7.87%
Poor
0.00%
Redington Ltd...
REDINGTON532805
54.7/100
322
₹22057.79
13.9
Average
16.86%
Good
18.39%
Good
0.3
Excellent
15.87%
Excellent
15.91%
Excellent
2.13%
MMTC Ltd...
MMTC513377
40.8/100
63
₹9682.50
96.8
Average
5.23%
Poor
8.66%
Poor
0.0
Excellent
2.89%
Average
-86.37%
Poor
0.00%
MSTC Ltd...
MSTCLTD542597
53.6/100
618
₹4612.62
21.1
Average
26.60%
Excellent
30.27%
Excellent
0.2
Excellent
14.13%
Good
-13.87%
Poor
6.19%
12.9/100
405
₹2670.18
77.7
Average
8.01%
Poor
4.38%
Poor
0.1
Excellent
0.00%
21.4/100
149
₹2312.81
32.0
Average
16.55%
Good
18.18%
Good
0.2
Excellent
0.06%
36.7/100
291
₹1458.56
23.1
Average
5.35%
Poor
5.65%
Poor
0.2
Excellent
0.00%
28.3/100
637
₹941.52
-13.71%
Poor
-11.12%
Poor
0.2
Excellent
47.55%
Excellent
0.00%
28.2/100
26400
₹808.37
15.5
Average
4.05%
Poor
4.13%
Poor
0.0
Excellent
-14.72%
Poor
4.72%
Average
1.90%
SMTEL...
SMTEL538563
62.59999999999999/100
418
₹763.91
33.1
Average
25.17%
Excellent
25.22%
Excellent
0.7
Good
154.57%
Excellent
167.25%
Excellent
0.00%
42.4/100
121
₹726.66
16.3
Average
25.83%
Excellent
0.00%

Norris Medicines Ltd Quarterly Performance

Latest quarterly metrics for NORRIS — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-48.16%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

121.74%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-7.87%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

14.21%

Compounded annual net profit growth over 5 years

Norris Medicines Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for NORRIS — calculated from daily price history

26RSI 14
Oversold — RSI 26

Selling pressure is heavy — potential reversal zone.

SMA 50
15
▲ Price above SMA 50 — Short-term bullish
SMA 200
15
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
2K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Norris Medicines Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Norris Medicines Ltd (NORRIS) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Norris Medicines Ltd

About NORRIS (Norris Medicines Ltd)

Norris Medicines Ltd is a dynamic trading and distribution company specializing in the procurement and delivery of a broad spectrum of pharmaceutical products and healthcare soluti...ons. Operating within the complex Indian pharmaceutical landscape, Norris acts as a critical link connecting manufacturers with a vast network of retailers, hospitals, and healthcare providers. The company meticulously manages its supply chain, ensuring timely and efficient distribution of essential medicines and healthcare products across diverse geographical regions. Norris is dedicated to maintaining the highest standards of quality and compliance, meticulously adhering to regulatory guidelines and industry best practices to safeguard the integrity of the products they handle. Norris Medicines Ltd distinguishes itself through its comprehensive portfolio of traded and distributed products, catering to a wide range of therapeutic areas. These include, but are not limited to, essential medications for common ailments, specialized treatments for chronic conditions, and various healthcare supplies designed to enhance patient well-being. Beyond simply moving products, Norris focuses on building strong relationships with both its suppliers and its customers, fostering trust and collaboration. They actively monitor market trends and patient needs, enabling them to adapt their offerings and ensure that healthcare professionals have access to the medications and tools they require to provide optimal care. Norris Medicines Ltd is committed to facilitating access to quality healthcare solutions throughout India. By strategically managing logistics, maintaining stringent quality control measures, and fostering collaborative partnerships, the company plays a vital role in the healthcare ecosystem. With a focus on reliability and efficiency, Norris strives to be a trusted partner for both manufacturers and healthcare providers, contributing to improved patient outcomes and a healthier community. They are driven by a commitment to ethical business practices and a dedication to supporting the evolving needs of the Indian healthcare sector.

Company Details

Symbol:NORRIS
Industry:Trading & Distributors
Sector:Trading & Distributors

Key Leadership

Mr. Vimal Dhirendra Shah
MD & Executive Director
Mr. Iqubal Ismail Patel
Chief Financial Officer
Ms. Priyanka Lohiya
Company Secretary & Compliance Officer

NORRIS Share Price: Frequently Asked Questions

What is the current share price of Norris Medicines Ltd?

Norris Medicines Ltd (NORRIS) trades at ₹14.91 on NSE and BSE. Market cap ₹15.70 (Cr). Educational data only.

What is the P/E ratio of Norris Medicines Ltd?

Norris Medicines Ltd has a P/E of N/Ax vs industry average 21.65x.

What is the Bull Run score for Norris Medicines Ltd?

Norris Medicines Ltd has a Bull Run score of 18.4/100 based on 25+ financial parameters.

Does Norris Medicines Ltd pay dividends?

Norris Medicines Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Norris Medicines Ltd?

Norris Medicines Ltd has ROE of N/A. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Norris Medicines Ltd?

Norris Medicines Ltd has debt-to-equity of N/A.

Is Norris Medicines Ltd a good investment?

Bull Run gives Norris Medicines Ltd a score of 18.4/100. This is not investment advice — consult a SEBI-registered advisor.